SavedAdd your journal

Journals / İstanbul Kuzey Klinikleri / 2020 / Cilt: 7 - Sayı: 1

Helicobacter pylori treatment in Turkey: Current status and rational treatment options

Tolga DÜZENLİ
Mustafa KAPLAN
Alpaslan TANOĞLU
Ayşe Nurdan TOZUN
Pages
87–94
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thus, each country/region needs torevise its own therapeutic results and the efficacy of various eradication regimens in the treatment of Helicobacter pylori.This report aims to review the current status of Helicobacter pylori treatment in Turkey and to provide recommendations forrational therapeutic considerations for the eradication of the bacterium.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:According to the TURHEP study, the prevalence of Helicobacter pylori in Turkey is 82.5%.
📊
Key Findings & Data:After FDA approval in 1995, manycountries have used standard triple therapy (proton pump inhibitor 40 mg b.i.d clarithromycin 500 mg b.i.d and amoxicillin 1gr b.i.d) for Helicobacter pylori treatment.
💡
Conclusion & Impact:Thus, each country/region needs torevise its own therapeutic results and the efficacy of various eradication regimens in the treatment of Helicobacter pylori.This report aims to review the current status of Helicobacter pylori treatment in Turkey and to provide recommendations forrational therapeutic considerations for the eradication of the bacterium.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

According to the TURHEP study, the prevalence of Helicobacter pylori in Turkey is 82.5%. After FDA approval in 1995, manycountries have used standard triple therapy (proton pump inhibitor 40 mg b.i.d clarithromycin 500 mg b.i.d and amoxicillin 1gr b.i.d) for Helicobacter pylori treatment. In the beginning, eradication rates were above 90% in many countries; however,current studies have demonstrated a prominent decrease in successful treatment rates, even down to 60%. This unfavorable reduction stimulated searches for new treatment protocols. Treatment protocols differ according to country, prevalence,cost-effectiveness, antibiotic resistance, CYP2C19 polymorphism and eradication rates. Thus, each country/region needs torevise its own therapeutic results and the efficacy of various eradication regimens in the treatment of Helicobacter pylori.This report aims to review the current status of Helicobacter pylori treatment in Turkey and to provide recommendations forrational therapeutic considerations for the eradication of the bacterium.

🔖

Cite This Article

DÜZENLİ, T., KAPLAN, M., TANOĞLU, A., TOZUN, A. N. (2022). Helicobacter pylori treatment in Turkey: Current status and rational treatment options. İstanbul Kuzey Klinikleri, Cilt: 7 - Sayı: 1, 87–94. https://ajindex.com/articles/551376

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011;20:299–304
  2. Ozaydin N, Turkyilmaz SA, Cali S. Prevalence and risk factors of Helicobacter pylori in Turkey: a nationally-representative, cross-sectional, screening with the ¹³C-Urea breath test. BMC Public Health 2013;13:1215
  3. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273–5
  4. Peleteiro B, Bastos A, Ferro A, Lunet N. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci 2014;59:1698–709
  5. Jung YS, Park CH, Park JH, Nam E, Lee HL. Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis. Helicobacter 2017;22
  6. Losurdo G, Leandro G, Principi M, Giorgio F, Montenegro L, Sorrentino C, et al. Sequential vs. prolonged 14-day triple therapy for Helicobacter pylori eradication: the meta-analysis may be influenced by ‘geographical weighting’. Int J Clin Pract 2015;69:1112–20
  7. Bor S, Kitapcioglu G, Kasap E. Prevalence of gastroesophageal reflux disease in a country with a high occurrence of Helicobacter pylori. World J Gastroenterol 2017;23:525–32
  8. Bayındır Bilman F, Özdemir M, Baysal B, Güzel Kurtoğlu M. Prevalence of H. pylori in gastric biopsy specimen in the southeastern region of Turkey. J Infect Dev Ctries 2016;10:1177–82
  9. Uyanikoglu A, Coskun M, Binici DN, Kibar YI, Tay A, Ozturk Y. Evaluation of gastroscopic and pathologic results in Erzurum region. Türkiye Klinikleri J Gastroenterohepatol 2011;18:70–4
  10. Leja M, Axon A, Brenner H. Epidemiology of Helicobacter pylori infection. Helicobacter 2016;21 Suppl 1:3–7
  11. Xin Y, Manson J, Govan L, Harbour R, Bennison J, Watson E, et al. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterol 2016;16:80
  12. Matsuhisa T. The trend of Helicobacter pylori infection rate: time, region, race and strain. Helicobacter Res 2015;19:469–80
  13. Anand PS, Nandakumar K, Shenoy KT. Are dental plaque, poor oral hygiene, and periodontal disease associated with Helicobacter pylori infection? J Periodontol 2006;77:692–8
  14. Kim SY, Choi DJ, Chung JW. Antibiotic treatment for Helicobacter pylori: Is the end coming? World J